CB2 selective sulfamoyl benzamides: Optimization of the amide functionality

Allan J. Goodman, Christopher W. Ajello, Karin Worm, Bertrand Le Bourdonnec, Markku A. Savolainen, Heather O'Hare, Joel A. Cassel, Gabriel J. Stabley, Robert N. DeHaven, Christopher J. LaBuda, Michael Koblish, Patrick J. Little, Bernice L. Brogdon, Steven A. Smith, Roland E. Dolle

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Previous research within our laboratories identified sulfamoyl benzamides as novel cannabinoid receptor ligands. Optimization of the amide linkage led to the reverse amide 40. The compound exhibited robust antiallodynic activity in a rodent pain model when administered intraperitoneally. Efficacy after oral administration was observed only when ABT, a cytochrome P450 suicide inhibitor, was coadministered.

Original languageEnglish
Pages (from-to)309-313
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Issue number2
StatePublished - Jan 15 2009


  • Antiallodynia
  • CB1
  • CB2
  • Cannabinoid
  • Sulfamoyl benzamides


Dive into the research topics of 'CB2 selective sulfamoyl benzamides: Optimization of the amide functionality'. Together they form a unique fingerprint.

Cite this